期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

三阴性乳腺癌及其研究进展 被引量：4

下载PDF
导出
摘要 乳腺癌是一种异质性非常高的肿瘤，它在分子生物学特征、病理及免疫表型和对治疗的反应等多方面都存在着明显的差异。三阴性乳腺癌（triple negative breast carcinoma，TNBC）是指雌激素受体（estrogen receptor，ER）、孕激素受体（proges-terone receptor，PR）和人表皮生长因子受体-2（human epider-mal growth factor receptor 2，HER2）均阴性表达的乳腺癌，被认为是一种独立的临床病理类型，具有侵袭性强、预后差的特点。由于内分泌治疗和针对 HER-2的靶向治疗对其几乎无效，故其治疗手段极其受限，探索新的治疗靶点成为当务之急。本文就近年来该类型乳腺癌的研究进展进行综述。
作者 朱鸿静 张春梅 杨清 陈广业 周仕娴 李敏
机构地区 荣昌县人民医院病理科 江津区中心医院病理科
出处 《国际检验医学杂志》 CAS 2014年第17期2350-2352,共3页 International Journal of Laboratory Medicine
关键词 三阴性乳腺癌 生物学特征 化疗 靶向治疗
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献27

  • 1Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours[J]. Nature,2000,406(6797) :747-752.
  • 2Llm E, Wu D, Pal B, et all Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways[J]. Breast Cancer Res, 201 0, 12 (2) : 21.
  • 3Visvader JE. Cells of origin in Cancer[J]. Nature, 2011. 469 (7330) :314 322.
  • 4Bertucci F,Finetti P,Cervera NA, et al. How basal are triple-neg- ative breast cancers? [J].Int J Cancer, 2008,123(1):236240.
  • 5Nielsen TO, Hsu FD,Jensen K, et al. Immunohistocheraical and clinical characterization of the basal-like subtype of invasive breast earcinnma[J]. Clin Cancer Res, 2004, 1 0 (1:6) : 5367-5374.
  • 6Visvader Jg. Keeping abreast of the mammary epithelial bierarehy and breast tumorigenesis [J]. Genes Dev, 2009, 2a (22) : 2563 2577.
  • 7Lim E, Vaillant F, Wu D, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation earriers[J]. Nat Med, 2009,15 (8) : 907-913.
  • 8Molyneux G, Geyer FC, Magnay FA, et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells[J]. Cell Stem Cell, 2010, 7 (a) : 408- 417.
  • 9Gonzalez Angulo AM, Timms KM, Liu SY, et al. Incidence and ou*eome of BRCA mutations in unseleeted patients with triple Re- ceptor-Negative breast Cancer[J]. Clin Cancer Res, 2011,17 (5) 1082-1089.
  • 10Dent R, Trudeau M, Pritchard KI, et al. Triple negalive breast Cancer: clinical features and patterns of recurrence[J]. Clin Canc- er Res,2007,13(15 Pt 1):4429 4434.

二级参考文献69

  • 1魏兵,步宏,Anthony Rhodes,张红英.英国国家免疫细胞化学外部质量评估方案及其乳腺病理应用模式[J].中华病理学杂志,2004,33(4):394-395. 被引量：10
  • 2杨名添,戎铁华,黄植蕃,曾灿光,龙浩,傅剑华,林鹏,王欣,王思愚,王曦,唐军.可手术乳腺癌6263例临床分析[J].癌症,2005,24(3):327-331. 被引量：46
  • 3Cleator S,Heller W,Coombes RC.Triple-negative breast cancer:Therapeutic options[J].Lancet Oncol,2007,8(3):235.
  • 4Eneman JD,Wood ME,Muss HB.Selecting adjuvant endocrine therapy for breast cancer[J].Oncology,2004,18(14):1733-1744.
  • 5Michaud LB.Treatment-experienced breast cancer[J].Am J Health Syst Pharm,2008,65(10 Suppl 3):4-9.
  • 6Perou CM,Sorlie T,Eisen MB,et al.Molecular portraits of human breast tumors[J].Nature,2000,406:747-752.
  • 7Kreike B,van Kouwenhove M,Horlings H,et al.Gene expression profiling and histopathological characterization of triple negative/basal-like breast carcinomas[J].Breast Cancer Res,2007,9:65.
  • 8Blackstein M,Vogel CL,Ambinder R,et al.Gemcitabine as firsfline thempy in patients with metastatic breast cancer:a phase Ⅱ trial[J].Oncology,2002,62(1):2-8.
  • 9Brodowicz T,Kostler WJ,Moslinger R,et al.Single-agent gemeitabine as second-line and third-line treatment in metastatic breast cancer[J].Breast,2000,9(6):338-342.
  • 10Bhattacharyya A,Ear US,Koler BH,et al.The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin[J].J Biol Chem,2000,275(31):23899.

共引文献78

同被引文献69

  • 1王理金.中医治疗乳腺癌的研究[J].医学信息（医学与计算机应用）,2014,0(6):522-522. 被引量：3
  • 2闫成.三阴性乳腺癌的临床研究进展[J].医学信息(下旬刊),2013,26(10):694.
  • 3张宇,李积德.三阴性乳腺癌的分子病理学特征及其治疗进展[J].中国保健营养(中旬刊),2012(4):640-641.
  • 4Bryan BB,Schnitt SJ,Collins LC.Ductal carcinoma in situ with basal-like phenotype:a possible precursor to invasive basal-like breast cancer[J].Mod Pathol,2006,19(5):617-621.
  • 5Goldhirsch A,Wood WC,Coates AS,et al.Strategies for subtypes dealing with the diversity of breast cancer:highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J].Ann Oncol,2011,22(8):1736-1747.
  • 6Siziopikou K,Cobleigh M.The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies[J].Breast,2007(16):104-107.
  • 7DENT R,TRUDEAU M,PRITCHARD KI,et al.Triple negative breast cancer:clinical features and patterns of recurrence[J].Clin Cancer Res,2007,13(15):4429-4434.
  • 8WU J,LI S,JIA W,et al.Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triplenegative breast cancer[J].J Cancer Res Clin Oncol,2011,137(10):1505-1510.
  • 9Kashiwagi S,Yashiro M,Takashima T,et al.Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at StageⅡ:usefulness of prognostic markers E-cadherin and Ki67[J].Breast Cancer Res,2011,13(6):122.
  • 10Perez EA,Patel T,Moreno-Aspitia A.Efficacy of ixabepilone in ER/PR/HER2-negative(triple-negative)breast cancer[J].Breast Cancer Res Treat,2010,121(2):261-271.

引证文献4

二级引证文献14

国际检验医学杂志
2014年 第17期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部